Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

Study of SRF388 in Patients With Advanced Solid Tumors

Miscellaneous

This is a Phase 1 / 1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Miscellaneous
I
Rini, Brian
NCT04374877
VICCMDP2083